Cipla vs Apollohosp Q1 FY25

Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing. North America hit an all-time high of $250 million (+13% YoY), supported by Lanreotide generic launch and Albuterol market share gains to 17%. India branded prescription grew 10% YoY, while trade generic transition was completed, impacting near-term growth. PAT stood at INR 1,178 crore (17.6% of sales). Management guided EBITDA margin of 24.5%-25.5% for FY25 and expects U.S. sustainable run rate of $235-240 million. Key risks include Goa facility FDA classification (six 483 observations) and potential price erosion in Albuterol with new entrants.

Guidance read

EBITDA margin guidance of 24.5%-25.5% for FY25: Management reiterated EBITDA margin range of 24.5%-25.5% for the full year, despite strong Q1 performance. U.S. sustainable quarterly run rate of $235-240 million: Expect U.S. business to settle at $235-240 million per quarter going forward, excluding one-time benefits. Two peptide launches expected in H2 FY25: Two additional peptide products are expected to launch in Q3 and Q4 of FY25, with two more following in subsequent years. Advair filing by end of 2024, potential launch in H1 CY2025: ANDA filing for Advair expected by December 2024 or January 2025, with potential launch in first half of calendar 2025.

Risk read

Key risks include Goa facility FDA classification pending — Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.; Potential price erosion from new Albuterol entrants — New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.; Lanreotide supply constraints limiting ramp-up — Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.; Trade generic transition disruption — Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains..

Promise ledger

Scorecard data is being built as historical quarters are processed.

Apollo Hospitals delivered a strong Q1 FY25 with consolidated revenue of INR 5,086 crore (+15% YoY) and EBITDA of INR 675 crore (+33% YoY). PAT surged 83% YoY to INR 305 crore. The hospital business saw inpatient volumes grow 11% YoY and occupancy rise 600bps to 68%, driven by insurance penetration (now 47% of revenue) and medical team expansion (102 doctors added). Apollo HealthCo reported positive EBITDA of INR 23 crore, with 24/7 digital losses narrowing to INR 97 crore. Management guided for 100bps margin expansion in hospitals over 3-4 quarters and 24/7 breakeven in 6-7 quarters. Risk: slower-than-expected ARPOB recovery due to higher medical case mix and potential disruption from Bangladesh political situation (2% of revenue).

Guidance read

Hospital margin expansion of 100bps over 3-4 quarters: Management expects healthcare services EBITDA margin to expand by 100 basis points over the next 3-4 quarters, driven by volume growth, case mix improvement, and cost optimization. ARPOB growth of 7% for FY25: Management guided for ARPOB increase of 7% for the full year, supported by tariff revision of 4%, better case mix, and international patient recovery. Apollo 24/7 digital breakeven in 6-7 quarters: The digital segment is on track to achieve breakeven within the next six to seven quarters, supported by GMV growth and cost control. 500-550 new pharmacy stores in FY25: Apollo HealthCo plans to add 500-550 new offline pharmacy stores in FY25, with Q1 impacted by election delays but pace expected to pick up.

Risk read

Key risks include Bangladesh political situation impacting international patients — Bangladesh contributes ~30% of international patient revenue (2% of total revenue). Recent political issues have caused a drop in volumes, though management expects recovery.; Slower ARPOB recovery due to higher medical case mix — ARPOB grew only 2% YoY due to a higher proportion of medical admissions. Management expects improvement but there is risk if surgical volumes do not pick up as anticipated.; New hospital bed additions may pressure margins — Operationalization of four new hospitals (1,500 beds) over next five quarters could reduce EBITDA margins by 100-150bps from FY25 exit levels..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.